INCIDENCE OF CONDUCTION SYSTEM DISTURBANCES AFTER EVOQUE TRICUSPID VALVE IMPLANTATION
Recommended Citation
Rangavajla G, Patel R, Abdelhai OS, Nguyen F, Gupta K, Fang JX, Giustino G, Raad M, Villablanca PA, Engel Gonzalez P, O’Neill BP, Frisoli TM. INCIDENCE OF CONDUCTION SYSTEM DISTURBANCES AFTER EVOQUE TRICUSPID VALVE IMPLANTATION. J Am Coll Cardiol 2025; 85(12):1126.
Document Type
Conference Proceeding
Publication Date
4-1-2025
Publication Title
J Am Coll Cardiol
Keywords
adult, atrioventricular block, complication, conference abstract, controlled study, female, follow up, heart left bundle branch block, heart right bundle branch block, human, implantation, incidence, male, pacemaker implantation, surgery, tricuspid valve, tricuspid valve prosthesis, tricuspid valve regurgitation, tricuspid valve replacement
Abstract
Background: EVOQUE transcatheter tricuspid valve replacement (EVOQUE) is a new treatment for severe tricuspid regurgitation. The initial TRISCEND study suggested a high risk of post-EVOQUE conduction system disturbance (CSD) with 13.3% of non-paced patients requiring new pacemakers. The incidence of real-world CSD with EVOQUE is less clear. Methods Patients undergoing commercial EVOQUE at Henry Ford Hospital (HFH) in Detroit, MI were monitored both in-hospital and outpatient for new CSD. Baseline characteristics and outcomes were compared to published results from TRISCEND using Z tests. Results Of 34 HFH patients undergoing successful EVOQUE, 22 had no prior pacemaker and were included for outcomes analyses. Baseline differences between HFH and TRISCEND patients are noted (Table 1). Over a median follow up of 92 days (IQR 55-148), only 1 patient required a post-implant pacemaker (Table 2) which was implanted 5 days after EVOQUE for high-grade AV block. Three of 5 developing new right bundle branch block had resolution within 30 days; no patient developed left bundle branch block or sinus pauses <5 seconds. Conclusion Real-world EVOQUE patients may have significantly lower rates of post-EVOQUE pacemaker implantation and CSD compared to published results. Registry data is needed to determine the veracity of this finding in larger samples. [Formula presented]
Volume
85
Issue
12
First Page
1126
